Abstract
Tyrosine kinase inhibitors (TKIs) have dramatically improved the clinical outcome and prognosis for chronic myelogenous leukemia (CML) patients. However, some patients develop acquired resistance to TKI treatment. Several mechanisms for imatinib resistance in CML have been proposed, and “biomarkers” are used at diagnosis and during TKI treatment to predict CML patient outcome. In this chapter, we discuss prognostic scoring systems used at diagnosis such as the Sokal score, Hasford score, European Treatment and Outcome Study score, early molecular response to TKI as a surrogate endpoint, pharmacokinetic factors such as plasma concentration of TKIs, polymorphisms of drug transporters, immunological biomarkers such as T-cell profiling, and a common intronic deletion polymorphism in the gene-encoding BCL2-like 11 (BIM) as candidates for biomarkers associated with clinical endpoints.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
